M Cdical/health surveillance of health care workers who handle cytotoxic agents has generated dialogue and debate. This is caused by the ambiguity created by the lack of specific laboratory methods and scientific rationale for performing comprehensive, nonspecific physical assessments, regarded by many as costly and time consuming tools for monitoring at-risk employees. What health and safety organizations recommend versus what is practical and meets the individualized needs of a hospital organization can be difficult to discern when work practices and engineering controls keep exposure minimal.
Occupational health clinicians are responsible for sorting through the minutia of recommendations and scicntilic data available related to cytotoxic drug exposure to playa fundamental role in creating a comprehensive hospital policy and protocol for employees handling hazardous drugs. This column describes the process of developing an appropriate medical/ health surveillance program for heallh care workers who handle cytotoxic drugs. The discussion includes examination of the recommended guidelines by health and safety organizations and discussion related to the rationale for the practice dilemmas
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Ms, DesRoches is Nurse Practitioner, Employee Health Sciences, Emory Healthcare, Atlanta, Georgia. 106 these recommendations create. The future of medical/health monitoring for cytotoxicdrug handlers, caused by greatly improved biological monitoring techniques, is also explored.
BACKGROUND
Anti-neoplastic, cytotoxic medications are considered hazardous, and are recognized as causing serious health effects including genetic damage, fertility problems, organ toxicity, birth defects, and cancer. Individuals who manufacture, administer, prepare, and dispose of cytotoxic medications are the population at-risk for exposure to these agents and are largely composed of nurses, physicians, and pharmacists in the hospital setting (OSHA, 1999) . Studies in the 1980s demonstrated objectively that exposure to cytotoxins created adverse health effects. For example, the cytotoxicdrug. cyclophosphamide was found in the urine of nurses and pharmacy technicians handling the drug, despite safety measures.
Health care workers administering cytotoxic agents have demonstrated a higher rate of spontaneous abortion and poor reproductive outcomes (Sotaniernie, 1983) . Lightheadedness, headaches, nausea, and allergic reactions have been reported by health care workershandlingcytotoxicdrugs in poorly ventilated areas, and pentamidine aerosol exposure has been linked to the onset of bronchospasm (Doll, 1989) . These types of studies hastenedthe need to delineate mechanisms to prevent and control occupational exposure to hazardousdrugs, to which the Occupational Safety and Health Administration (OSHA) and American Society of Hospital Pharmacists (ASHP) responded.
MECHANISMS TO PREVENT AND CONTROL EXPOSURE
Hospital institutions should develop a hazardous drug and safety plan. This written document needs to address a multitude of elements, including a basic operating procedure in the event of health care worker exposure to cytotoxic drugs. Engineering controls are expected to be in place. particularly the use of biological safety cabinets with ventilation to the outside. These types of cabinets have been shown to greatly reduce exposure to cytotoxic agents during drug preparation.
Appropriate ventilation systems should be in place and maintained to ensure proper functioning. Worker training and education programs need to emphasize the use and availability of personal protective equipmentsuch as gloves, gowns, respiratory protection, and eye and face protection. These work practices are essential elements in exposure control and should also include universal precautions, as well as instruction about special handling of intravenous tubing, needles, ampules. and vials.
A system for safe disposal of contaminated materials such as sharps, vials, ampules, and bags should be developed. and designated drug handling areas need to in place. The plan also should ensure that the use of Food and Drug Administra-tion investigational drugs are approved by the hospital, and appropriate committees are established to ensure dissemination of the plan. The drug safety and health plan should be reviewed on an annual basis (OSHA, 1999) .
Medicallhealth surveillance for cytotoxic drug handlers is aimed at minimizing or eliminating exposure to cytotoxic agents. The OSHA recommends a comprehensive medical/ health surveillance program, including evaluation of at-risk employees at the time of hire, periodically, postexposure, and at departure. This includes a detailed history of the employee's duties, anticipated exposure levels, personal protective equipment used, and medical history. Special attention should be given to a history of malignancies and hepatic and hematopoietic disorders.
A detailed occupational history is fundamental in the history intake and includes environmental sampling information related to past exposures. If environmental sampling data are not accessible, the history should outline type, amounts, and hours of drugs previously handled. A complete physical examination should be performed, emphasizing cardiopulmonary function, liver, skin, mucous membranes, and lymphatics. If indicated, an assessment of respiratory use should be addressed.
Laboratory tests may include liver function tests, a complete blood count with differential, blood urea nitrogen, creatinine, and a urine dipstick. Further laboratory tests are determined based on specific toxicities for a given drug. However, currently there are no recommended biological monitoring tests of significant prognostic value to warrant routine testing for cytotoxic drug handlers.
The occupational health clinician has discretion in determining how often periodic examinations should be performed, based on the employee's history related to the likelihood and duration of exposure to cytotoxic agents. Fundamental to the periodic examination is information related to routine and accidental exposures to cytotoxic drugs. A complete physical examination and laboratory stud- 
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ies should follow the same format as the pre-placement assessment.
The exit examination and laboratory studies are balled on the exposure history of the employee, and are similar to the periodic examination. Postexposure assessments include completion of an incident report, a problem specific history, a physical examination, and treatment based on the material safety data sheet (MSDS) for the specific drug as well as established protocols (OSHA, 1999) .
Exposures should also be reported on a confidential database and be in compliance with the access to employee exposure and medical records standard 29 CFR 1910.1020 (OSHA, 20(1). The data are expected to include a MSDS, pertinent information related to drugs handled, use of personal protective equipment, engineering controls, and the post-exposure medical assessment and treatment rendered details.
CHALLENGES IN MEASURING EXPOSURES
While the OSHA recommendations for cytotoxic drug handlers are comprehensive, their practical application in occupational health settings is at times challenging. Because OSHA recommendations appeared in 1986 and ASHP recommendations in 1990, many health care organizations have implemented them in their medical/health surveillance programs only to find that monitoring seldom generates valuable information. The crux of this dilemma relates to the difficulty with being able to scientifically measure exposure to cytotoxic agents, and thus aim interventions accordingly.
Currently, there are no acceptable safe levels of exposure to hazardous drugs. The effects of cytotoxic drug exposure can vary greatly depending on the specific drug in question and differences in secondary biological effects among individuals who are exposed to these drugs. Worker safety practices, engineering controls and amount of time spent working with cytotoxic agents are factors that also impact the actual risk to a health care worker (OSHA, 1999) .
Gathering a detailed history intake becomes imperative for all potential hazardous drug handlers in estimating the amount of risk to cytotoxic agents for a given employee, including the amount of time spent handling hazardous drugs. The most essential controls for individuals handling cytotoxic drugs are the use of biological safety cabinets and worker education programs (McDiarmid, 1990) .
Complete physical examinations have often been found to be minimally useful, but if performed should focus on target organs affected by cytotoxic agents. Laboratory work at hire and on periodic assessment for all employees with some level of cytotoxic drug handling has been found to be costly without yielding relevant information. The premise for obtaining lab work is related to the idea that while complete blood counts with differential, creatinine, blood urea nitrogen. urine dipstick. and liver function tests are nonspecific, they serve to establish baseline data. Any deviation from baseline alerts the clinician to a possible exposure to cytotoxic drugs. On the other hand, if the exposure is such that abnormal laboratory values found from performing these tests are unlikely to be related to cytotoxic drug exposure, the occupational health clinician is in a difficult position of attempting to determine the cause of the abnormal results, while explaining the results are not likely caused by an exposure.
Biological markers specific to exposure to a given cytotoxic agent are needed to better monitor cytotoxic drug exposure and hold promise for the future. Some advances have been made in this area, including the use of gas chromatography for examining urinary excretion of unmetabolized particles. Using this method, urinary excretion of the cytotoxic drugs cyclophosphamide and ifosfamide by health care workers can be more accurately measured (Ensslin, 1994) . If the biological monitoring tests have a high sensitivity, increasing the likelihood beyond a reasonable doubt that results are caused by occupational exposure to a given cytotoxic agent, there is sound rationale for employee occupational health departments to use these methods as a part of their medical/health surveillance and postexposure management programs (Sessink, 19(9). In formulating a hospital policy and protocol for health care workers handling cytotoxic drugs, it is essential to usc available information from technical guidelines as a basis for practice, but tailored to the specific needsof a given hospital organization. For example, the institution that reserves all preparation of cytotoxic agents to pharmacy stuff may need 10 do a more comprehensive medical/ health surveillance assessment for this group of health care workers. Conversely, the nurse or physician who docs not have to prepare medication but only administer it needs to adhere to safe practice guidelines, but may not be a part of a group that needs baseline lab work and frequent and comprehensive follow up assessment.
SUMMARY
Many advances have been made in the area of cytotoxic drug handling Clinical Rounds: Hospital link among health care workers. The publication of technical guidelines in the late 19801' and early 1990s have served a fundamental role in increasing awareness of the potential risk to health care workers exposed to cytotoxic agents. The OSHA and ASHP guidelines have greatly assisted occupational health professionals in developing appropriate policyfor their hospital institution. However, with their use during the years, the guidelines have been criticized as impractical and not very useful. Occupational health professionals welcome the changes on the horizon as research uncovers newand better waysto monitor high risk employees.
